Bariatric Surgery Cardiac Outcomes

Issues of Concern

Bariatric surgery produces substantial weight loss and improves comorbid conditions, but it carries inherent risks. Although uncommon, perioperative cardiovascular complications require careful risk stratification. In a large meta-analysis by Chang et al, perioperative myocardial infarction occurred in 0.37% of cases.[8] A 2025 comprehensive review of over 1.2 million procedures reported perioperative mortality (≤30 days) of 0.08% (95% CI, 0.06–0.11%) for primary procedures, with technique-specific mortality rates of 0.03% to 0.08% for sleeve gastrectomy, 0.01% to 0.05% for ASGB, 0.07% to 0.2% for RYGB, and 0.2% to 0.5% for BPD.[9]

A retrospective analysis of 13,722 patients who underwent bariatric surgery at the Cleveland Clinic Health System in the United States, including 2287 who underwent metabolic surgery, revealed varying complication rates. Negative outcomes following metabolic surgery included postoperative bleeding requiring transfusion in 3.0% of patients, pulmonary adverse events in 2.5%, venous thromboembolism (VTE) in 1.0%, cardiac events in 0.7%, and renal failure requiring dialysis in 0.2%. Abdominal surgical intervention in the immediate postoperative period was required in 4.8% of the metabolic surgery group. Mortality within 90 days of the initial procedure occurred in 0.7% of patients.

Despite these complications, metabolic surgery was associated with reduced incidences of all prespecified outcomes. These outcomes included all-cause mortality, coronary disease, cerebrovascular events, heart failure, atrial fibrillation, and nephropathy.[10] A retrospective analysis involving 135,413 patients who underwent bariatric surgery identified the most common complications within 30 days of surgery as bleeding (0.7%), wound infection (0.5%), urinary tract infection (0.3%), VTE (0.3%), and anastomotic leak (0.2%). Postoperative stroke and myocardial infarction occurred in 0.01% and 0.04% of patients, respectively.

Adverse events such as bleeding and anastomotic leaks contributed substantially to end-organ dysfunction, requiring reoperation and intensive care unit admission during the postoperative period. VTE and stroke represented the highest mortality risk among all complications following bariatric surgery.[11] Morino et al conducted a comprehensive retrospective analysis using an extensive prospective database encompassing 13,871 bariatric procedures: 6,122 ASGB, 4215 vertical banded gastroplasties, 1106 gastric bypasses, 1988 BPDs, and 303 biliointestinal bypasses. The analysis reported a 60-day mortality rate of 0.25%, with procedure type significantly influencing mortality risk. Mortality rates were 0.1% for ASGB, 0.15% for vertical banded gastroplasties, 0.54% for gastric bypasses, and 0.8% for BPD. Pulmonary embolism accounted for the primary cause of death (38.2%), followed by cardiac failure (17.6%), intestinal leak (17.6%), and respiratory failure (11.8%). Technical complications directly caused death in 29.4% of cases.

Factors including open surgery, prolonged operative time, perioperative hypertension or diabetes, and case volume at each center were associated with increased mortality risk. These findings highlight the importance of selecting an appropriate procedure and ensuring surgical team expertise when performing bariatric surgery. Although bariatric surgery is generally safe, the specific procedure type remains a critical determinant of mortality risk.[12] Overall perioperative risk remains low and is influenced by procedure selection, patient risk stratification, and surgical expertise.

Clinical Significance

Extensive evidence demonstrates a significant reduction in cardiovascular risk factors following bariatric surgery, establishing therapeutic benefit beyond cosmetic effects and confirming its effectiveness in preventing cardiovascular events. The impact of bariatric surgery on cardiovascular risk reduction is substantial. Evidence consistently shows superior long-term weight loss compared with the best available nonsurgical therapies for obesity, regardless of procedure type.

More than 250,000 bariatric procedures are performed annually in the United States, reflecting broad recognition of cardiovascular benefit.[13] Recent large-scale investigations have quantified these effects. A 2022 Medicare analysis of 189,770 beneficiaries demonstrated associations with reductions in all-cause mortality (37%), new-onset heart failure hospitalizations (54%), myocardial infarction (37%), and ischemic stroke (29%) over a median follow-up of 4 years.[14]

Heart Failure 

Significant weight loss following bariatric surgery improves cardiac metabolism, workload, performance, and structure. Bariatric surgery is associated with reductions in left ventricular end-diastolic volume, left ventricular mass (LVM), and left atrial diameter, as well as increases in left ventricular ejection fraction (LVEF). Improvements in diastolic and systolic function, as well as myocardial structure, have been documented in patients undergoing bariatric surgery.[15][16] A meta-analysis of 39 studies demonstrated a significantly lower incidence of heart failure among individuals treated with bariatric surgery compared with nonsurgical management.[17]

Electrocardiographic and Echocardiographic Changes 

Weight loss after bariatric surgery is associated with reductions in resting heart rate and shortening of the corrected QT interval on electrocardiogram. Postoperative electrocardiographic findings commonly include rightward axis shift, fewer criteria for hypertrophy, lower QRS voltage, and reduced T-wave flattening.[18] Echocardiographic evaluation at 6 months demonstrates significant reductions in left ventricular dimensions and LVM, with an increase in the early-to-late ventricular filling velocity (E/A) ratio.[19][20]

A systematic review and meta-analysis of 80 studies including 3332 patients demonstrated statistically significant improvements in cardiac geometry and function, including a 12.2% reduction in LVM index, an increase of 0.155 in E/A ratio, a 2.0 mm reduction in left atrial diameter, a 1.16 mm reduction in left ventricular diastolic dimension, and a 1.6% increase in LVEF.[21] Cardiac structural and functional improvements are detectable within 3 to 6 months postoperatively. A 2024 study of 398 consecutive patients with preoperative and postoperative echocardiography demonstrated significant reductions in LVM (205 g to 190 g; P < 0.001), improvement in LVEF (58% to 60%; P < 0.001), and enhancement of left ventricular global longitudinal strain (-15.7% to -8.6%; P < 0.001).[22]

Atrial Fibrillation 

Atrial fibrillation is associated with diabetes mellitus, hypertension, obstructive sleep apnea, and obesity. Emerging evidence supports bariatric surgery as an intervention to reduce atrial fibrillation risk in individuals with obesity. A secondary analysis of the Look AHEAD (Action for Health in Diabetes) trial demonstrated that nonsurgical weight loss did not significantly reduce the incidence of atrial fibrillation.[23]

A 2019 meta-analysis similarly reported limited evidence supporting a reduction in atrial fibrillation incidence following nonsurgical weight loss. The same analysis found that a 5% weight gain was associated with a 13% increase in the incidence of atrial fibrillation.[24] Preventing weight gain in the general population remains essential to reducing the global burden of atrial fibrillation. A 2023 meta-analysis of 10 studies evaluating incident atrial fibrillation demonstrated that bariatric surgery, compared with medical therapy, was associated with a reduced incidence of atrial fibrillation.[25]

Dyslipidemia and Hypertension 

Multiple studies demonstrate significant reductions in triglyceride levels at 12 months after bariatric surgery. The same studies report increases in high-density lipoprotein cholesterol over the same period.[26][27] A meta-analysis by Buchwald et al evaluated 135,246 subjects who underwent bariatric surgery and reported substantial improvement in preexisting metabolic disorders. Hypertension resolved in 61.7% of patients, while dyslipidemia and diabetes mellitus improved in 70% and 86% of patients, respectively. Findings support bariatric surgery as an effective intervention to improve metabolic health.[28]

A 2012 study of 19,543 subjects assessed the effects of bariatric surgery on cardiovascular risk factors and cardiac structure and function. Resolution or improvement of baseline hypertension, diabetes mellitus, and hyperlipidemia occurred in a significant proportion of patients following surgical intervention.[29] A separate meta-analysis by Wilhelm et al reported improvement in hypertension in 63.7% of patients and complete resolution in 50% of patients undergoing bariatric surgery.[30]

Atherosclerosis 

Carotid intima-media thickness is a validated marker for predicting cardiovascular disease and progression of atherosclerosis. Bariatric surgery in patients with morbid obesity results in a significant reduction in carotid intima-media thickness.[31]

Diabetes 

Type 2 diabetes is strongly associated with obesity. Resolution of type 2 diabetes following bariatric surgery is well documented. Fasting plasma glucose and hemoglobin A1c levels decrease markedly within 12 months after surgery.[32] Fasting plasma glucose can decline within 1 week of the procedure.[33] Surgical intervention also reduces the need for oral antidiabetic agents and insulin therapy.[34] Pender et al reported improved insulin receptor sensitivity and increased skeletal muscle insulin receptor concentrations following bariatric surgery.[35]

Weight Loss

A 2019 study analyzed the health records of 13,722 patients from the Cleveland Clinic Health System in the United States. Of these patients, 2287 underwent metabolic surgery, while 11,435 served as controls. Metabolic surgical procedures included RYGB, sleeve gastrectomy, ASGB, and duodenal switch. The study demonstrated a decreased risk of major cardiovascular events associated with metabolic surgery. Over 8 years, patients undergoing surgery achieved an average weight loss of 29.1 kg, compared with 8.7 kg in the control group. Hemoglobin A1c levels were also significantly lower in the surgical group, indicating improved glycemic control after surgery.

Lifespan and Deaths from Cardiovascular Disease 

Bariatric surgery consistently reduces cardiovascular disease risk factors. The Swedish Obese Subjects study demonstrated that, compared with traditional care, bariatric surgery was associated with fewer deaths from cardiovascular disease and a lower incidence of cardiovascular events in adults with obesity.[36] Patterson et al reported that laparoscopic gastric bypass for severe obesity was associated with a longer lifespan than a diet and exercise regimen. Life expectancy after surgery was 69.7 years, compared with 67.3 years for patients maintained on diet and exercise alone.[37]

A 2007 study by Adams et al compared long-term mortality in 9949 patients who underwent gastric bypass surgery with a control group of 9628 individuals with severe obesity who applied for driver’s licenses, matching 7925 patients from each group. Long-term mortality was significantly lower after gastric bypass, particularly for deaths due to diabetes, heart disease, and cancer. Mortality from nondisease causes was higher in the surgery group than in the control group.[38]

A 2021 cohort study evaluated the association between bariatric surgery and major adverse cardiovascular events (MACE) in patients with cardiovascular disease and severe obesity. Bariatric surgery was associated with a lower incidence of MACE in this population.[39] A 2022 meta-analysis of 39 prospective and retrospective studies demonstrated that bariatric surgery reduced overall mortality and cardiovascular mortality. Incidents of heart failure, myocardial infarction, stroke, and atrial fibrillation were also lower among patients who underwent bariatric surgery.

Cardiovascular Disease Risk in Patients with Nonalcoholic Fatty Liver Disease

A large-scale retrospective cohort study examined the association between bariatric surgery and cardiovascular disease risk in adults with metabolic dysfunction–associated steatotic liver disease and severe obesity. The study included 86,964 adults, of whom 30,300 (34.8%) underwent bariatric surgery, and 56,664 (65.2%) received nonsurgical care. Inverse probability treatment weighting balanced baseline covariates. The surgical group experienced 1568 cardiovascular events, compared with 7215 events in the nonsurgical group. Bariatric surgery was associated with a 49% lower risk of cardiovascular disease than nonsurgical care, indicating a substantial reduction in cardiovascular risk in individuals with severe obesity and nonalcoholic fatty liver disease.[40]

Comparison with Glucagon-Like Peptide 1 Receptor Agonists

Bariatric (metabolic) surgery demonstrates superior cardiovascular outcomes compared with glucagon-like peptide 1 (GLP-1) receptor agonist (GLP-1 RA) therapy. A 2025 study compared 1,657 patients who underwent metabolic surgery with 2,275 patients treated with GLP-1 RAs over a median follow-up of 5.9 years. The 10-year cumulative incidence of all-cause mortality was significantly lower in the bariatric surgery group than in the GLP-1 RA group. Bariatric surgery was also associated with reduced risk of MACE, nephropathy, and retinopathy.[41]

A 2025 meta-analysis of 5 cohort studies including 39,569 patients confirmed these findings. Bariatric surgery was associated with a 43% lower risk of all-cause mortality, a 35% reduction in MACE, and a 55% lower risk of heart failure compared with GLP-1 RA therapy. These differences corresponded to 25 fewer deaths, 25 fewer cardiovascular events, and 23 fewer cases of heart failure per 1000 patients treated.[42]

Overall, these studies indicate that, despite the expanding availability and efficacy of GLP-1 receptor agonists, metabolic surgery remains superior to medical therapy for long-term cardiovascular outcomes. Future comparative studies should assess whether these advantages persist with newer-generation GLP-1–based therapies that achieve greater and more durable weight reduction. The above benefits reflect global cardiometabolic risk reduction rather than isolated cardiac effects. Further discussion of the broader metabolic and biomechanical complications associated with obesity is available in a separate activity.[43]

Other Issues

Dumping Syndrome

Dumping syndrome is a postprandial phenomenon frequently observed after bariatric surgery. Rapid transit of food from the stomach into the small intestine without complete digestion produces gastrointestinal and vasomotor symptoms, including fatigue, abdominal pain, nausea, vomiting, diarrhea, and hypotension. Hypotension results from a rapid osmotic fluid shift from plasma into the bowel, which can induce tachycardia and syncope. Symptoms are often alleviated through dietary and lifestyle modifications.[44]

Thiamine Deficiency

Bariatric surgery reduces the absorptive surface area of the stomach and may cause deficiencies in essential vitamins, including thiamine (vitamin B1). Severe, prolonged thiamine deficiency can result in Wernicke encephalopathy, characterized by ataxia, nystagmus, and confusion.[45] Thiamine deficiency may also cause wet beriberi, which typically presents with cardiovascular symptoms, signs of heart failure, and fluid accumulation.[46] Intravenous thiamine administration before glucose is the recommended treatment for Wernicke encephalopathy and wet beriberi, as glucose alone can exacerbate Wernicke encephalopathy. Due to unpredictable gastrointestinal absorption, oral thiamine should be avoided in patients with malnutrition.[47]

Iron Deficiency

Iron deficiency is common after RYGB. Contributing factors include reduced dietary iron intake, decreased hydrochloric acid secretion, and diminished absorptive surface area.[48] A study of 170 patients who underwent RYGB reported iron-deficiency anemia in 6.5% before surgery and 33.5% at 3 years postoperatively. Premenopausal women exhibited lower hematocrit and hemoglobin levels following the procedure.[49] Iron-deficiency anemia has been associated with elevated systemic inflammation, promoting atherosclerosis and increasing cardiovascular event risk, particularly in women.[50]

Oral iron supplementation constitutes the primary treatment for iron deficiency after RYGB. Nausea and constipation are common adverse effects, often leading to noncompliance and persistent deficiency.[51] Intravenous iron supplementation may be required for patients who cannot tolerate oral therapy or fail to respond. Intravenous iron carries a risk of anaphylaxis and is rarely considered a 1st-line therapeutic agent.[52] Administration of 2 g of intravenous iron dextran effectively treats anemia and replenishes iron stores for over a year in most patients who have undergone RYGB. This regimen is safe and effective and can improve symptoms such as fatigue and pica.[53]

Perioperative Considerations for Patients on Glucagon-Like Peptide 1 Receptor Agonists

The increasing use of GLP-1 RAs for weight loss requires careful consideration of perioperative management, including the optimal timing of discontinuation before surgery. GLP-1 RAs delay gastric emptying, which may elevate the risk of pulmonary aspiration during anesthesia. A 2025 gastric ultrasound study found that 35.8% of patients receiving GLP-1 RAs had high residual gastric content despite adherence to standard preoperative fasting guidelines. Withholding weekly injections for 7.5 days or less was associated with a higher prevalence of elevated gastric residuals.[54] In response, the US Food and Drug Administration has added warnings to all GLP-1 RA labels regarding the risk of pulmonary aspiration during procedures requiring general anesthesia or deep sedation.[55]

Emerging evidence highlights potential benefits of perioperative GLP-1 RA use in bariatric surgery. A 2025 systematic review demonstrated that preoperative GLP-1 RA therapy was associated with greater preoperative weight loss, earlier metabolic optimization, and improved glycemic outcomes, although it was also associated with more frequent postoperative nausea. Preoperative GLP-1 RA use was not associated with increased risk of major postoperative complications or hospital readmissions.[56]

A cohort study of 112,858 individuals reported rising GLP-1 RA use among individuals undergoing bariatric surgery, most commonly after the 2nd postoperative year, driven by increasing BMI.[57] The rapid adoption of GLP-1 RAs among candidates for bariatric surgery, combined with evidence that standard fasting intervals may be insufficient, necessitates careful preoperative evaluation. The assessment should explicitly examine GLP-1 RA use and implement individualized risk-stratification protocols.

Enhancing Healthcare Team Outcomes

Bariatric surgery, also referred to as metabolic and weight loss surgery, represents an effective therapeutic intervention for severe obesity and its associated comorbidities, particularly cardiovascular disease. Eligibility generally includes a BMI above 40 kg/m², or above 35 kg/m² with conditions such as type 2 diabetes, hypertension, or obstructive sleep apnea. Common procedures include Roux-en-Y gastric bypass, sleeve gastrectomy, adjustable gastric banding, biliopancreatic diversion with duodenal switch, and intragastric balloon placement.

These interventions reduce gastric capacity and, in some cases, nutrient absorption, resulting in substantial and sustained weight loss. Evidence demonstrates improvements in metabolic parameters and reductions in cardiovascular events, heart failure, atrial fibrillation, and mortality. Despite these benefits, bariatric surgery carries perioperative risks and long-term complications, including venous thromboembolism, bleeding, dumping syndrome, and nutritional deficiencies that require careful monitoring.

Optimal outcomes depend on coordinated interprofessional care. Clinicians evaluate surgical eligibility, perform risk stratification, and guide long-term management of obesity-related comorbidities. Surgeons collaborate with anesthesiologists and cardiology specialists to mitigate perioperative cardiovascular risk. Nurses provide perioperative monitoring, patient education, and postoperative support, while pharmacists assist with medication adjustments, micronutrient supplementation, and the management of therapies such as glucagon-like peptide-1 receptor agonists. Dietitians and other health professionals support nutritional counseling and long-term lifestyle modification. Effective communication among team members promotes appropriate procedure selection, early recognition of complications, and adherence to follow-up care, improving patient safety, cardiometabolic outcomes, and long-term weight management.

Nursing, Allied Health, and Interprofessional Team Interventions

Selection of the most appropriate bariatric procedure requires careful consideration of the specific risks associated with each surgery. Postoperative mortality risk may be minimized by prioritizing the optimal surgical method, implementing preventive measures, promptly identifying complications, and providing targeted cardiovascular care. Regular postoperative assessments with the bariatric surgeon and primary care provider are essential. These evaluations monitor progress, detect adverse events, and guide medication adjustments. Referrals to other specialists, including a registered dietitian, mental health professional, and exercise physiologist, may be required to ensure comprehensive care.

The registered dietitian plays a pivotal role in ensuring adherence to the prescribed postoperative dietary regimen. The mental health professional provides support and intervention for psychosocial challenges, including body dysmorphia or mood disturbances. The exercise physiologist develops safe and effective exercise programs essential for promoting weight loss and maintaining overall physical health. Postoperative evaluations and consultations with specialized healthcare providers are critical for long-term success after bariatric surgery. Attendance at these appointments and adherence to the healthcare team’s recommendations substantially increase the likelihood of positive outcomes and improvement in overall quality of life.